Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Nurexone Biologic Inc fell by 1.92m. Cash Flow from Financing totalled 1.13m or -- of revenues. In addition the company used 2.94m for operations while cash used for investing totalled 97.00k.
Cash flow per share | -0.1058 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.052 |
---|---|
Tangible book value per share | 0.052 |
More ▼
Balance sheet in USDView more
Current ratio | 5.10 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0097 |
---|---|
Total debt/total capital | 0.0096 |
More ▼